JLE

Hématologie

MENU

New molecular classifications of diffuse large-cell lymphomas Article à paraître

  • [1] Alizadeh A.A., Eisen M.B., Davis R.E. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. 6769
  • [2] Swerdlow S.H., Campo E., Harris N.L. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
  • [3] Grimm K.E., O’Malley D.P. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol. 2019;38:6-10.
  • [4] Staiger A.M., Ziepert M., Horn H. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin's lymphoma study group. J Clin Oncol. 2017;35:2515-2526. 22
  • [5] Davies A., Cummin T.E., Barrans S. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649-662. 5
  • [6] Jardin F. Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge. Lancet Oncol. 2019;20:605-606. 5
  • [7] Younes A., Sehn L.H., Johnson P. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285-1295. 15
  • [8] Reddy A., Zhang J., Davis N.S. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481-94 e15. 2
  • [9] Schmitz R., Wright G.W., Huang D.W. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396-1407. 15
  • [10] Dubois S., Viailly P.J., Bohers E. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin Cancer Res. 2017;23:2232-2244. 9
  • [11] Lee Y.S., Liu J., Fricano K.A. Lack of a prognostic impact of the MyD88 L265P mutation for diffuse large B cell lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:2199-2204. 12
  • [12] Yu S., Luo H., Pan M. High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. Oncol Lett. 2018;15:1707-1715. 2
  • [13] Chapuy B., Stewart C., Dunford A.J. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679-690. 5
  • [14] Dubois S., Jardin F. Novel molecular classifications of DLBCL. Nat Rev Clin Oncol. 2018;15:474-476. 8
  • [15] Ennishi D., Jiang A., Boyle M. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:190-201. 3
  • [16] Sha C., Barrans S., Cucco F. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37:202-212. 3
  • [17] Evrard S.M., Pericart S., Grand D. Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Haematologica. 2019;104:e154-e157. 4
  • [18] Milpied P., Cervera-Marzal I., Mollichella M.L. Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. Nat Immunol. 2018;19:1013-1024. 9
  • [19] Sha C., Barrans S., Care M.A. Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Med. 2015;7:64. 1
  • [20] Leonard J.P., Martin P., Roboz G.J. Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol. 2017;35:2708-2715. 23
  • [21] Chiche J., Reverso-Meinietti J., Mouchotte A. GAPDH expression predicts the response to R-CHOP, the tumor metabolic status, and the response of DLBCL patients to metabolic inhibitors. Cell Metab. 2019;29:1243-1257. 6
  • [22] Beguelin W., Popovic R., Teater M. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23:677-692. 5
  • [23] Morin R.D., Johnson N.A., Severson T.M. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181-185. 2
  • [24] Pastore A., Jurinovic V., Kridel R. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111-1122. 9
  • [25] Qi W., Zhao K., Gu J. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol. 2017;13:381-388. 4
  • [26] Wang J.Q., Jeelall Y.S., Ferguson L.L., Horikawa K. Toll-like receptors and cancer: MYD88 mutation and inflammation. Front Immunol. 2014;5:367.
  • [27] Pham-Ledard A., Cappellen D., Martinez F., Vergier B., Beylot-Barry M., Merlio J.P. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2012;132:2118-2120. 8
  • [28] Kraan W., van Keimpema M., Horlings H.M. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28:719-720. 3
  • [29] Yamada S., Ishida Y., Matsuno A., Yamazaki K. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015;56:2141-2145. 7
  • [30] Dubois S., Viailly P.J., Bohers E. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin Cancer Res. 2017;23:2232-2244. 9
  • [31] Knittel G., Liedgens P., Korovkina D. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood. 2016;127:2732-2741. 22
  • [32] Taniguchi K., Takata K., Chuang S.S. Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma. Am J Surg Pathol. 2016;40:324-334. 3
  • [33] Kraan W., Horlings H.M., van Keimpema M. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.
  • [34] Camus V., Sarafan-Vasseur N., Bohers E. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57:2171-2179. 9
  • [35] Zhang J., Davis N., Moffitt A. Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa. Blood. 2017;130:37. Suppl 1